Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 16/20 | 0.70 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.52 |
| ▸ | PRKCA | P17252 | 4/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624661 | 0.90 | PRKCQ (0.70) | PRKCQPRKCDPRKCAKCNH2JAK2 | |
| SCHEMBL9917879 | 0.87 | PRKCQ (0.74) | PRKCQPRKCDPRKCAKCNH2TLR9 | |
| SCHEMBL9917881 | 0.85 | PRKCQ (0.75) | PRKCQPRKCDPRKCAKCNH2JAK2 | |
| SCHEMBL9917834 | 0.85 | PRKCQ (0.74) | PRKCQPRKCDPRKCAKCNH2JAK2 | |
| SCHEMBL9917880 | 0.82 | PRKCQ (0.74) | PRKCQPRKCDPRKCAKCNH2JAK2 | |
| SCHEMBL9917740 | 0.82 | PRKCQ (1.00) | PRKCQPRKCDPRKCAKCNH2JAK2 | |
| SCHEMBL9917781 | 0.82 | PRKCQ (0.48) | PRKCQPRKCDJAK2ROCK2ROCK1 | |
| SCHEMBL9917741 | 0.80 | PRKCQ (1.00) | PRKCQPRKCDPRKCAKCNH2JAK2 | |
| SCHEMBL9917868 | 0.79 | PRKCQ (1.00) | PRKCQPRKCDPRKCAKCNH2JAK2 | |
| SCHEMBL9917836 | 0.79 | PRKCQ (0.68) | PRKCQPRKCDPRKCAKCNH2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291937-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCD 120/4885PRKCA 25/4885 |
| US-20120149680-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885PRKCD 120/4885PRKCA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.